文献速递中药与中成药合理使用

中成药产品进入中国医保体系的市场准入机制:对传统医学国际整合的启示

Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems.
PubMed 文献 · Chin Med · 2022-01-04

本文采用文献分析定性方法,从四个来源收集数据并进行主题分析,识别出管理创新品牌与通用中成药进入、价格调整和退出医保的四种机制:价格谈判、价格再谈判、集中采购和直接调出。结论认为中国已建立以创新品牌药价格谈判和通用药集中采购为核心的中成药市场准入框架,并呼吁基于真实世界数据开展临床与药物经济学研究以支持准入。

要点

  • 创新品牌中成药通过价格谈判进入国家医保目录。
  • 目录内创新品牌中成药通过价格再谈判调整价格。
  • 通用中成药通过集中采购进入医保体系,直接调出机制负责退出。

核心结论

  • 中国已建立以创新品牌中成药价格谈判和通用中成药集中采购为核心的市场准入框架。
  • 需进一步开展基于真实世界数据的研究,为中成药进入医保体系提供临床与药物经济学证据。

研究设计与样本

  • 采用文献分析定性研究方法,数据来自四个来源,以主题分析方式处理。

主要发现

  • 识别出四种管理创新品牌与通用中成药进入、价格调整和退出医保的机制。
  • 机制包括价格谈判、价格再谈判、集中采购和直接调出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: China has introduced a series of polices and practice to manage the market access of Chinese patent medicine (CPM) products into its healthcare security system, which is less analyzed and reported in current literature. Therefore, this paper aimed to investigate the mechanisms managing market access of CPM products into healthcare security system in China, expecting to provide implications for international integration of traditional medicine products into health systems. METHOD: This paper used a documentary analysis approach as a qualitative research method. Data were collected from four sources and analyzed in a thematic way. RESULTS: Four mechanisms to manage entry, price adjustment, and exit of innovative brand and generic CPM products are identified, including: (1) price negotiation, mechanism of new entry of innovative brand CPM products into the national reimbursement list; (2) price re-negotiation, mechanism of price adjustment of innovative brand CPM products within the national reimbursement list; (3) mass procurement, mechanism of generic CPM products to healthcare security system; and (4) direct removal, mechanism of removal from the national reimbursement list. CONCLUSIONS: China has established market access framework of CPM products by focusing on price negotiation for innovative brand CPM products and mass procurement for generic CPM products. Further studies of CPM products based real-world data are needed to provide clinical and pharmacoeconomic evidence to support market access of CPM products into healthcare security systems.

来源:Chin Med,查看原文。版权归原作者所有。

引用

  1. Xia C, Yao D, Lai Y, et al. Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems. Chin Med. 2022. PMID: 34983590. doi:10.1186/s13020-021-00560-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。